search
EADV
Trends
- 1EADV Congress 2026 Opens With Six Key Headlines▼EADV Congress 2026: Day 1 Recap — 6 Headlines to Know
The European Academy of Dermatology and Venereology has begun its 2026 Congress, with day one yielding six headline developments in dermatology and venereology. Coverage highlights new clinical findings and treatment updates presented at the meeting, which brings together skin-health specialists from around the world. Attendees and medical media are summarising the most notable announcements as the congress continues.
- 2Rezpegaldesleukin Shows Long-term Benefits in Alopecia Areata and Eczema▼New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026
New data on rezpegaldesleukin, an immunotherapy developed by Nektar Therapeutics, will be presented at the EADV Congress 2026, showing long-term durability of response and disease improvement in patients with alopecia areata and atopic dermatitis. The findings support the drug's potential as a durable treatment for these chronic immune-mediated skin conditions, and investors and dermatology specialists are following the data closely.
- 3
Day 2 of the European Academy of Dermatology and Venereology Congress 2026 is in the books, with a recap highlighting six key headlines from the meeting. Coverage is focused on the latest dermatology research, clinical trial results and practice updates presented to specialists gathered from around the world.
- 4Two-Year Data for Alopecia Drug LEQSELVI Shows Sustained Efficacy▼New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026
Sun Pharmaceutical announced two-year clinical data for LEQSELVI (deuruxolitinib) in severe alopecia areata, presented at the EADV Congress 2026. The results showed sustained efficacy and a consistent safety profile in patients over the extended treatment period. The findings reinforce the drug's long-term value for people with severe hair loss, though discussion so far appears limited to the announcement itself.
- 5New Biomarker Data on Rezpegaldesleukin Presented at EADV Congress 2026●New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
New biomarker data on rezpegaldesleukin were presented in a late-breaking oral presentation at the EADV Congress 2026. The findings show early molecular responses to the drug across multiple immune pathways that are dysregulated in patients with atopic dermatitis. The data suggest the therapy, an immune-regulating treatment, is being positioned as a potential option for the inflammatory skin condition, and the presentation is drawing attention from the dermatology community.
- 6CytoAgents Unveils New Preclinical Data on CTO1681●CytoAgents Presents New Preclinical CTO1681 Data at the 2026 EADV Congress
CytoAgents presented new preclinical data on its investigational compound CTO1681 at the 2026 EADV Congress, the European Academy of Dermatology and Venereology's annual meeting. The company says the findings support the drug candidate's development potential in dermatology. Details of the data and the indication being targeted have not been broadly reported, and the announcement is drawing attention from investors and dermatology specialists following the congress presentation.